title: Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.
abstract: LY210825, a recombinant tissue-type plasminogen activator (rt-PA), which contains the kringle-2 and serine protease functional domains of native tissue-type plasminogen activator, was previously produced by site-directed mutagenesis in a Syrian hamster cell line. We studied the thrombolytic potential of this molecule in a canine thrombosis model. Male hounds (16-22 kg) were anesthetized; a 2.0-cm segment of the left circumflex coronary artery (LCX) was isolated proximal to the first main branch, and the dogs were instrumented with an electromagnetic flow probe to measure coronary blood flow. An occlusive thrombus was formed after injury of the intimal surface of the LCX with an electrical current applied by a needle-tipped anode placed distal to the electromagnetic flow probe. After 1 hour of occlusion, either LY210825 or rt-PA was administered intravenously according to the following protocols: 1) a 1-hour infusion of either 0.25 mg/kg LY210825 or 0.4 mg/kg rt-PA, 2) single injections of 0.15-0.6 mg/kg LY210825, and 3) a single injection of 0.45 mg/kg LY210825 and a 3-hour infusion of 1.0 or 1.7 mg/kg rt-PA. Plasma half-lives of LY210825 and rt-PA were 58 +/- 7 and 3.3 +/- 0.3 minutes, respectively. LY210825 produced more rapid reperfusion of the LCX than did rt-PA. In the third study, 90% of the rt-PA-treated vessels reoccluded within 1 hour after cessation of drug, whereas only 25% of the LY210825-treated vessels reoccluded during a 4-hour washout period. There were significant, but relatively small, reductions produced by both plasminogen activators on plasma fibrinogen and plasminogen (25-35% decreases). Because of its longer plasma half-life, LY210825 could be administered intravenously as a single injection. In a canine model of coronary artery thrombosis, LY210825 was a more effective thrombolytic agent than was rt-PA.
authors.affiliation: Department of Cardiovascular Pharmacology, Eli Lilly and Company, Indianapolis, Indiana 46285.
authors.forename: C V
authors.initials: CV
authors.lastname: Jackson
authors.forename: V G
authors.initials: VG
authors.lastname: Crowe
authors.forename: T J
authors.initials: TJ
authors.lastname: Craft
authors.forename: J L
authors.initials: JL
authors.lastname: Sundboom
authors.forename: B W
authors.initials: BW
authors.lastname: Grinnell
authors.forename: J L
authors.initials: JL
authors.lastname: Bobbitt
authors.forename: P J
authors.initials: PJ
authors.lastname: Burck
authors.forename: J F
authors.initials: JF
authors.lastname: Quay
authors.forename: G F
authors.initials: GF
authors.lastname: Smith
mesh_terms: D000818:Animals; D001777:Blood Coagulation; D001798:Blood Proteins / Q000032:analysis; D003326:Coronary Circulation; D003327:Coronary Disease / Q000503:physiopathology*; D003328:Coronary Thrombosis / Q000097:blood / Q000503:physiopathology*; D004285:Dogs; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D011994:Recombinant Proteins; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000494:pharmacology*
chemical_list: D001798:Blood Proteins; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C065621:LY 210825; D010959:Tissue Plasminogen Activator